Characteristics at initial diagnosis
| Characteristic . | N = 81 . |
|---|---|
| Age (y) at initial diagnosis, median (IQR) | 12.0 (7.0-14.0) |
| Sex, n (%) | |
| Female | 27 (33) |
| Male | 54 (67) |
| Race, n (%) | |
| White | 54 (67) |
| Black | 11 (14) |
| Asian | 7 (8) |
| Other | 4 (5) |
| Unknown | 5 (6) |
| Ethnicity, n (%) | |
| Hispanic | 11 (14) |
| Non-Hispanic | 56 (69) |
| Unknown | 14 (17) |
| Stage at initial diagnosis, n (%) | |
| I | 5 (6) |
| II | 12 (15) |
| III | 38 (47) |
| IV | 23 (28) |
| Unknown | 3 (4) |
| CNS involvement, n (%) | |
| Positive | 7 (9) |
| Negative | 68 (84) |
| Unknown | 6 (7) |
| Initial treatment regimen, n (%) | |
| ALCL99 | 26 (32) |
| ANHL0131 | 11 (14) |
| ANHL12P1 with brentuximab | 25 (31) |
| ANHL12P1 with crizotinib | 9 (11) |
| Other | 10 (12) |
| Enrolled on clinical trial, n (%) | 17 (21) |
| Characteristic . | N = 81 . |
|---|---|
| Age (y) at initial diagnosis, median (IQR) | 12.0 (7.0-14.0) |
| Sex, n (%) | |
| Female | 27 (33) |
| Male | 54 (67) |
| Race, n (%) | |
| White | 54 (67) |
| Black | 11 (14) |
| Asian | 7 (8) |
| Other | 4 (5) |
| Unknown | 5 (6) |
| Ethnicity, n (%) | |
| Hispanic | 11 (14) |
| Non-Hispanic | 56 (69) |
| Unknown | 14 (17) |
| Stage at initial diagnosis, n (%) | |
| I | 5 (6) |
| II | 12 (15) |
| III | 38 (47) |
| IV | 23 (28) |
| Unknown | 3 (4) |
| CNS involvement, n (%) | |
| Positive | 7 (9) |
| Negative | 68 (84) |
| Unknown | 6 (7) |
| Initial treatment regimen, n (%) | |
| ALCL99 | 26 (32) |
| ANHL0131 | 11 (14) |
| ANHL12P1 with brentuximab | 25 (31) |
| ANHL12P1 with crizotinib | 9 (11) |
| Other | 10 (12) |
| Enrolled on clinical trial, n (%) | 17 (21) |
IQR, interquartile range.